Immunosuppressive Drug Use In Solid Organ Transplantation: off Label Use Characterization

Heart Liver Lung Kidney Patients: n (%) 23 (21.3) 14 (13.0) 41 (38.0) 30 (27.9) Age: median (P25-P75) 60 (54-64) 51 (46-57) 62 (57-65) 50 (34-59) Acute rejection: n (%) 5 (21.7) 1 (7.1) 17 (41.5) 6 (20.0) Fatal 1 (4.3) 0 1 (2.4) 0 Cellular 3 (13.0) 1 (7.1) 17 (41.5) 5 (16.7) Humoral 2 (8.7) 0 0 1 (3.3) Adverse events: n (%) 4 (17.4) 2 (14.3) 11 (26.8) 0 Required treatment 3 (13.0) 1 (7.1) 2 (4.9) 0 Required hospitalization 2 (8.7) 1 (7.1) 5 (12.2) 0 Infecctions: n (%) 4 (17.4) 8 (57.1) 15 (36.6) 2 (6.7) Bacterial 3 (13.0) 7 (50) 13 (31.7) 2 (6.7) Fatal 0 0 1 (2.4) 0 Induction Thymoglobulin 4* 0 0 18 Basiliximab 19* 4* 0 12 Maintenance Tacrolimus + Mycophenolate Tacrolimus + Mycophenolate *Tacrolimus + *Mycophenolate Tacrolimus + Mycophenolate + Corticoids + Corticoids + Corticoids + Corticoids